Yes, men can get breast cancer. Roughly 1 in 833 men will be diagnosed in their lifetime, and about 2,800 U.S. men are diagnosed each year, according to the National Cancer Institute. Men carry small amounts of breast tissue behind the nipple, and that tissue can undergo the same malignant transformation as a woman's. Male breast cancer is rare, typically appears later in life, and is more often driven by inherited BRCA2 mutations. Most men who find a lump in the breast do not have cancer, but any unilateral lump, nipple discharge, or skin change warrants a clinical exam.
The Anatomy: Why Men Have Breast Tissue at All
Every human embryo builds a basic mammary duct system before sex hormones redirect development. In males, testosterone suppresses further growth, but it does not erase the ducts. What remains is a rudimentary ductal tree embedded in a few cubic centimeters of fibrofatty tissue directly behind the nipple-areolar complex.
That residual tissue is small, typically under 2 cm thick in a lean adult man. It is also hormonally responsive, which matters more than its size. Breast tissue responds to estrogen, progesterone, and prolactin regardless of the sex of the person carrying it. When estrogen signaling rises relative to testosterone, that ductal tissue can proliferate.
In plain terms: men have the hardware for breast cancer. They just have far less of it, which is the single biggest reason the disease is rare in men.
The Mechanism: What Drives Malignant Change in Male Breast Tissue
Male breast cancer is overwhelmingly ductal. About 85 to 90 percent of cases are invasive ductal carcinoma, arising from the epithelial lining of those residual ducts. Lobular carcinoma, which starts in the milk-producing lobules, is rare in men because lobules are poorly developed without prolonged estrogen and progesterone cycling.
The molecular driver is hormone-receptor signaling. Roughly 90 percent of male breast cancers are estrogen-receptor positive, a higher share than in women. That receptor positivity is why endocrine therapy such as tamoxifen works well in men, and why survival outcomes for matched stages are similar between sexes.
The inherited pathway is the other major mechanism. A BRCA2 mutation raises a man's lifetime breast cancer risk to an estimated 7 to 8 percent, versus about 0.1 percent in the general male population. BRCA1 mutations confer a smaller but real elevation. This is why a man diagnosed with breast cancer is often the first person in a family to reveal a hereditary cancer syndrome.
A less obvious mechanism is hormonal imbalance from the environment. Conditions that raise estrogen or lower androgen, such as cirrhosis, obesity, Klinefelter syndrome, and testicular injury, all increase risk. So do some treatments, including certain prostate cancer therapies that suppress androgen signaling. The pattern is consistent: male breast tissue responds to the same hormonal arithmetic that governs the female breast.
Quantified Context: How Rare Is It, Really
The headline comparison is stark and worth stating precisely.
| Measure | Men | Women | Ratio (women to men) |
|---|---|---|---|
| Lifetime risk | ~1 in 833 | ~1 in 8 | ~104 to 1 |
| U.S. new cases per year | ~2,800 | ~310,000 | ~111 to 1 |
| U.S. deaths per year | ~530 | ~42,000 | ~79 to 1 |
| Median age at diagnosis | ~67 years | ~62 years | Men ~5 years later |
| Share that is ER-positive | ~90% | ~75-80% | Higher in men |
| 5-year relative survival, localized | ~87% | ~99% | Lower in men |
The survival gap deserves explanation rather than alarm. Men tend to be diagnosed at a later stage because neither patients nor clinicians expect breast cancer in a male chest. Stage for stage, survival is comparable. The difference is largely a detection and awareness effect, not a biological inferiority of treatment.
Male Breast Cancer Timeline: From First Sign to Follow-Up
The course of the disease follows a predictable arc, and the timeline matters because delays are common in men.
| Stage | Typical timing | What happens |
|---|---|---|
| Symptom onset | Day 0 | Painless lump behind nipple, or nipple discharge/retraction |
| Presentation delay | 1 to 10+ months | Men wait longer than women before seeking care |
| Diagnostic workup | 1 to 3 weeks | Clinical exam, diagnostic mammogram, ultrasound, core needle biopsy |
| Pathology and staging | 1 to 2 weeks | ER/PR/HER2 status, lymph node sampling, imaging for metastasis |
| Primary treatment | Weeks 3 to 8 | Mastectomy (most common) with or without axillary surgery |
| Adjuvant therapy | Months 2 to 8 | Chemotherapy if indicated, then tamoxifen typically for 5 years |
| Surveillance | Years 1 to 10 | Clinical exams, imaging as indicated, genetic counseling referral |
The presentation delay row is the actionable one. Men who present within a month of noticing a lump tend to have smaller tumors and better node status than those who wait six months or more.
Edge Cases and Variations: Genetics, Age, and Hormones
Three subgroups carry meaningfully elevated risk and deserve explicit mention.
Men with BRCA2 mutations face the 7 to 8 percent lifetime risk cited earlier, roughly 70 to 80 times the baseline. Men with Klinefelter syndrome, who carry an extra X chromosome and elevated estrogen, have a breast cancer risk estimated 20 to 50 times higher than other men. Men with a history of chest radiation, particularly for Hodgkin lymphoma in adolescence, also carry elevated risk.
Age is a quieter variable. Male breast cancer peaks in the mid-to-late 60s, about five years later than the female peak. A breast lump in a man under 40 is far more likely to be gynecomastia, a benign enlargement of glandular tissue, than cancer. Gynecomastia is common, often bilateral, and usually tender; cancer is typically unilateral, firm, and painless.
Corrected Misconceptions About Breast Cancer in Men
Several beliefs circulate that the evidence does not support.
The most persistent is that men cannot get breast cancer because they lack breasts. They have ductal tissue, and roughly 1 percent of all breast cancer diagnoses occur in men. The rarity is real; the impossibility is not.
A second misconception is that a male breast lump is always gynecomastia. Benign enlargement is indeed the most common cause, but assuming that without evaluation is how late-stage diagnoses happen. Any firm, unilateral, non-tender mass, especially with nipple discharge or skin dimpling, needs imaging and possibly biopsy.
A third is that male breast cancer is automatically more aggressive. Biology is broadly similar, and ER-positive disease responds to the same endocrine therapy. The apparent aggressiveness in registry data is largely a stage-at-diagnosis artifact. The counterintuitive professional caveat: male breast cancer is under-studied, and most treatment protocols are extrapolated from female trials rather than tested in men directly.
A fourth is that mastectomy is always required. It is the most common surgery in men because breast conservation is technically difficult in a small chest, but it is a practical preference, not a biological mandate.
Red Flags: When a Male Breast Change Needs Evaluation
These signs warrant a prompt clinical visit, not watchful waiting.
- A firm, unilateral lump behind the nipple that persists beyond two to four weeks
- Nipple discharge, especially bloody or spontaneous
- Nipple retraction, inversion, or crusting that is new
- Skin dimpling, puckering, or an orange-peel texture over the breast
- A lump fixed to the chest wall or skin, or associated with armpit swelling
- Any breast change in a man with a known BRCA2 mutation or prior chest radiation
What to Actually Do: Practical Steps for Men
The positive actions are straightforward and low-cost. Perform a brief self-check monthly: stand before a mirror, press fingertips in small circles across each breast and into the armpit, and note any firm, fixed, or new mass. This takes under two minutes.
If you find something, book a primary care visit within two weeks rather than waiting to see whether it resolves. Ask specifically for a diagnostic mammogram and ultrasound if the lump is unilateral and firm. A clinical breast exam plus imaging is the standard workup; a biopsy confirms the diagnosis.
Know your family history and share it. If a close relative has breast, ovarian, pancreatic, or prostate cancer, mention it, because a BRCA2 pattern can span all four. Men diagnosed with breast cancer should receive genetic counseling regardless of family history, since roughly 10 to 20 percent carry a pathogenic BRCA mutation.
If you take a medication that alters hormones, such as certain androgen-deprivation therapies or estrogen-containing products, ask your clinician whether breast surveillance is appropriate. And if you have Klinefelter syndrome or prior chest radiation, raise breast awareness with your care team at your next visit.
Limitations of the Evidence
Male breast cancer research is thin relative to its female counterpart. Most adjuvant chemotherapy and radiation protocols in men are extrapolated from trials that enrolled only women. Tamoxifen has reasonable male-specific data, but aromatase inhibitor evidence in men is weaker and confounded by concurrent testosterone suppression. Screening mammography is not recommended for average-risk men, and no major guideline endorses routine male breast screening outside high-risk groups. Risk figures such as the 1-in-833 lifetime estimate come from population registries and carry wide confidence intervals at the tail. The honest summary: the mechanism is well understood, the treatment is effective, and the evidence base is smaller than the disease deserves.